Dr. Rosa M. Abrantes-Metz's experience includes work in consulting and banking, as well as in government. Her main areas of specialization are econometrics, financial economics, monetary economics, and applied industrial organization. Dr. Abrantes-Metz is an Associate Adjunct Professor at Leonard N. Stern School of Business, New York University, where she teaches industrial economics. She has taught econometrics at the department of economics at the University of Chicago, and various other fields of economics at Universidade Catolica Portuguesa, in Lisbon, Portugal. Since working as a staff economist at the Federal Trade Commission, Dr. Abrantes-Metz continued serving as a consultant for special projects with the Commission's Bureau of Economics. She is the author of several articles on econometric methods, conspiracies and manipulations, gasoline, pharmaceuticals and healthcare, event studies, and has published in many peer-reviewed journals. Dr. Abrantes-Metz is a co-drafter of the chapter on the role of the economic expert in proving conspiracy cases under federal antitrust laws, a recent volume by the American Bar Association, and a contributor to other books on antitrust and international arbitration with a focus on event studies. Dr. Abrantes-Metz has developed numerous screens for conspiracies and manipulations, and is a pioneer in the field, contributing to the increased adoption of these empirical methods. She has flagged potential anti-competitive behavior preceding large-scale worldwide investigations, such as the alleged Libor conspiracy and manipulation (LIBOR Manipulation? (2008) and Tracking the Libor Rate (2010)). At the time the first investigations on Libor surfaced, Dr. Abrantes-Metz's work was covered by the Wall Street Journal and the Financial Times. Her screens are used by competition authorities worldwide and also by defendants. In pharmaceuticals, she has co-developed a model to estimate the likelihood of drugs failing and succeeding each of the clinical stages of the Food and Drug Administration, and their expected durations in each of these phases. This model has become one of the two most used by industry analysts to value pharmaceutical and biotechnology pipelines. Her research on pharmaceuticals and conspiracies has been discussed in books on how to value pharmaceutical and biotechnology companies, and on publications pertaining to healthcare, intellectual property and cartels. She has presented her work to competition authorities all over the world. Dr. Abrantes-Metz has provided testimony related to alleged bid-rigging and price-fixing, and in international arbitration on the valuation of expropriated assets.